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The role of radiotherapy in the treatment of hepatocellular carcinoma (HCC) has been limited to date, because the 
liver has a low tolerance to radiation. However, reconstructing tumors and surrounding organs via a three-dimensional 
conformal planning system can avoid excess radiotherapy exposure to the rest of the liver and adjacent organs. Recently, 
the concept of “adaptive radiotherapy,” such as with helical tomotherapy, has been introduced for treating HCC. Helical 
tomotherapy obtains an image from the computed tomography component, which allows targeted regions to be visualized 
prior to, during, and immediately after each treatment and delivers intensity-modulated radiation therapy. We report two 
patients with advanced HCC who underwent tomotherapy treatment. One was a patient afflicted with advanced HCC 
and a portal vein tumor thrombus, which was treated with tomotherapy combined with transarterial chemolipiodolization. 
The other was a patient afflicted with multiple pulmonary metastases treated with tomotherapy followed by systemic 
chemotherapy. (Korean J Intern Med 2011;26:201-206) 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
difficult malignancies to treat. Several modalities, including 
surgery, transcatheter arterial chemoembolization (TACE), 
radiofrequency catheter ablation, percutaneous ethanol 
injection therapy, radiotherapy, and liver transplantation, 
have been used and attempted in treating HCC. However, 
most patients have a poor prognosis because of a poor 
hepatic functional reserve, associated with cirrhosis, as 
well as unresectable and aggressive characteristics, such   
as adjacent vessel invasion and distant metastases.
Portal vein thrombosis due to invasion of the tumor 
into the portal vein occurs in 20-70% of patients with 
HCC [1], and has a poor prognosis compared with patients 
without portal vein thrombosis [2]. Currently, no standard 
treatment regimen has been established for patients 
afflicted with HCC combined with portal vein thrombosis. 
The most frequent site experiencing extrahepatic 
metastasis from HCC is the lung, and resection may 
prolong survival in selected cases [3-5]. Nevertheless, 
surgery is usually limited to patients with pulmonary 
metastasis or those with metastases at other sites. Few 
treatment modalities have been suggested for patients 
with advanced HCC with multiple lung metastases.
Rather than whole-liver radiation therapy (RT), targeted 
local RT has been attempted by several investigators and 
has revealed that high doses of radiation can be safely 
delivered to a portion of the liver [6]. This suggests possible 
beneficial effects of radiation and chemotherapy for 
advanced HCC with portal vein tumor thrombosis (PVTT). 
The most advanced radiation therapeutic techniques are 
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being developed for treating solid tumors. Among them, 
helical tomotherapy (HT) is an innovative approach for 
delivering intensity-modulated radiation therapy by 
combining the elements of helical computed tomography 
(CT) with megavoltage linear accelerator treatment [7].
Here, we report two cases of advanced HCC treated with 
HT. One patient was afflicted with PVTT and the other 
showed multiple lung metastases.
CASE REPORTS
Case 1
A 43-year-old male was admitted to Seoul St. Mary’s 
Hospital in January 2006. He had been a known hepatitis B 
carrier for 18 years, and abdominal sonography performed 
at the outpatient clinic incidentally revealed a mass in 
the right liver lobe. He had no history of diabetes or 
hypertension. Pertinent laboratory findings showed the 
following: a leukocyte count of 8,340/µL, hemoglobin 
concentration of 14.6 g/dL, platelet count of 251,000/
µL, prothrombin activity time of 85%, aspartate 
aminotransferase of 38 IU/L, alanine aminotransferase of 
62 IU/L, alkaline phosphatase of 180 IU/L, total bilirubin 
of 0.68 mg/dL, total protein concentration of 7.3 g/dL, 
and an albumin concentration of 3.05 g/dL. Serological 
tests performed on the patient to test for the hepatitis B “s” 
and “e” antigens were positive. Furthermore, the serum 
alpha-fetoprotein (AFP) concentration was 8.04 ng/mL. 
CT revealed a diffuse infiltrative HCC involving the right 
hepatic lobe with tumor thrombosis involving the right 
portal vein and the proximal portion of the left portal vein 
(Fig. 1A and 1B). HT treatment was targeted at the site of 
the portal vein thrombosis. The patient was immobilized 
with a whole-body vacuum, low-pressure foil (Body 
Fix System, Medical Intelligence, Schwabmuenchen, 
Germany) to minimize respiratory motion of the 
tumor and internal organs. A daily dose of 5 Gy was   
Figure 1. Abdominal computed tomography (CT) scan reveals a diffuse infiltrative hepatocellular carcinoma involving the right hepatic 
lobe (A) with a portal vein thrombosis (B). Abdominal CT 2 months after transcatheter arterial chemoembolization and tomotherapy 
showed improvement in the right infiltrative mass (C) and portal vein thrombosis (D). Abdominal CT 6 months after the initial treatment 
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administered, at five fractions per week, to deliver a total 
dose of 50 Gy (Fig. 2). We performed CT scans at 2 (Fig. 
1C and 1D) and 6 months (Fig. 1E and 1F) after treatment, 
which showed markedly improved portal vein thrombosis. 
After HT treatment, an intra-arterial chemoport was 
inserted at the hepatic artery 1 month later, and the patient 
received four cycles of chemotherapy with a monthly 
regimen of cisplatin (60 mg/m
2), epirubicin (50 mg/m
2), 
and 5-fluorouracil (200 mg/m
2). One year after receiving 
HT, a 2-cm arterial enhancing nodule was discovered on 
the hepatic dome of the liver. The patient subsequently 
received successful radiofrequency ablation (RFA) for the 
enhancing nodule. He is currently alive and has been in 
good health for 23 months with subsequent successful 
treatments after the HCC diagnosis.
Case 2
A 42-year-old female patient with HCC visited Seoul 
St. Mary’s Hospital in January 2006. She was diagnosed 
with HCC in 2001 and had received a right hepatectomy 
at another hospital. Three years after the surgery (August 
2004), she visited our hospital, and a lung metastasis 
was discovered. She received six intermittent cycles of 
chemotherapy from 2004 to 2005. After the six cycles 
of chemotherapy, she refused to visit the hospital. The 
laboratory findings upon admission showed the following: 
a leukocyte count of 2,500/µL, hemoglobin concentration 
of 11.5 g/dL, platelet count of 50,000/µL, prothrombin 
time activity of 78%, aspartate aminotransferase of 36 
IU/L, alanine aminotransferase of 31 IU/L, alkaline 
phosphatase of 94 IU/L, total bilirubin of 0.65 mg/dL, 
total protein of 6.8 g/dL, and an albumin concentration 
of 3.86 g/dL. Additionally, serum AFP was 926.3 ng/
mL. We performed chest X-rays upon admission, which 
showed an increase in the size of the metastatic lung 
lesions compared with her previous chest X-rays from 
11 months earlier (Fig. 3A). The chest CT also showed an 
increase in the size of multiple metastatic lung lesions, but 
no increase in number (Fig. 3D). A CT of the abdomen also 
revealed an interval increase in the size of the HCC in the 
Figure 2. Tomotherapy targeting the portal vein tumor thrombosis was administered at a daily dose of 5 Gy for a total dose of 50 Gy.204    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
hepatic dome, compared with the abdominal CT from 1 
year earlier. The patient received HT for her multiple lung 
lesions, with a daily regimen of 3-5 Gy, at five fractions 
per week, for a total dose of 30-50 Gy to each metastatic 
lung lesion (Fig. 4). A chest X-ray was performed at 2 and 
6 months after the HT and revealed a marked decrease 
in the size of the multiple lung nodules (Fig. 3B and 
3C). A chest CT similarly showed a vast decrease in the 
size of the lung nodules (Fig. 3E and 3F). Serum AFP 2 
months after HT was 224.1 ng/mL. The patient received 
systemic chemotherapy treatment on a monthly regimen. 
Six months after receiving HT, a brain CT showed newly 
developed brain metastases. She received HT again for her 
multiple brain lesions, according to the same treatment 
protocol for her metastatic lung lesions (data not shown). 
A brain CT was performed at 3 months after the HT and 
revealed a marked decrease in the size of the multiple 
brain masses. She was alive 16 months after the initial HT 
for multiple metastatic lung tumors and died 6 months 
after receiving brain HT due to bleeding from a newly 
developed metastatic brain tumor.
DISCUSSION
Until recently, the role of radiotherapy in advanced 
HCC had been limited due to the poor tolerance of the 
entire liver to radiation [8]. Recently, local RT has been 
investigated for treating HCC. In particular, recent 
advances in three-dimensional conformal radiotherapy 
have allowed us to minimize unwanted irradiation to 
normal liver tissue, and, therefore, facilitate maximal 
escalation of the radiation dose to the critical organs 
without a significant increase in toxicity [6]. HT uses 
Figure 3. Chest X-rays show multiple metastatic lung lesions (A). Chest X-ray 2 months (B) and 6 months (C) after tomotherapy showed 
a marked decrease in the size of the multiple lung nodules. Chest computed tomography (CT) on admission showed multiple metastatic 
lung lesions with the largest lesion measuring 5.5 cm in diameter (D). Chest CT 2 months later shows a marked decrease in the size of the 
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intensity-modulated radiation fan beams to deliver a 
highly conformal dose distribution to the patient [7].
Portal vein thrombosis and lung metastases are common 
in patients with advanced HCC [4]. Both complications are 
associated with a poor prognosis; however, no standard 
treatment regimen has been established. Although TACE 
shows statistically significant survival benefits in patients 
with unresectable HCC [9], controversy remains over the 
benefit for patients with portal vein thrombosis. TACE 
has generally been contraindicated for these patients 
because of potential ischemic liver damage [10]. However, 
several studies have been conducted in which TACE was 
successfully performed in patients with good hepatic 
reserve or collateral circulation around the main portal 
vein [6].
The lungs are the most common site of extrahepatic 
spread of HCC [3], and pulmonary resection for metastasis 
prolongs survival in selected cases [3,4]. Furthermore, 
some authors have reported using curative resection 
to prolong survival, even in patients with multiple lung 
metastases [5]. However, in clinical practice, surgery 
is usually restricted to patients with a good pulmonary 
reserve and a solitary metastasis. Thus, few patients are 
suitable for this surgery.
Here, we describe two cases of advanced HCC treated 
with HT and combined chemotherapy. One patient had 
a portal vein thrombosis, which resolved after HT and 
additional hepatic artery infusion chemotherapy, whereas 
the other patient exhibited a vast decrease in the size 
of multiple lung nodules treated with HT and systemic 
chemotherapy. One year after receiving HT, the first 
patient developed a new arterial enhancing mass in the 
hepatic dome and received RFA for the hepatic mass. Six 
months after the RFA, the patient currently shows no 
sign of tumor recurrence. No significant adverse effect 
of HT occurred during the 23-month follow-up period. 
The second patient died 16 months after receiving HT. 
Imaging studies performed 6 months after HT revealed 
brain metastases. The patient survived 16 months after 
receiving lung HT, and no significant adverse effect 
Figure 4. Tomotherapy was performed with a daily regimen of 3-5 Gy for patients with multiple lung nodules.206    The Korean Journal of Internal Medicine Vol. 26, No. 2, June 2011
developed. HT combined with chemotherapy achieved a 
good response and longer survival in these two cases of 
advanced HCC with a portal vein tumor thrombosis and a 
lung metastasis.
Recently, many precise radiation techniques have been 
developed to treat solid tumors [11]. Our cases suggest 
that PVTT and pulmonary metastasis are amenable 
to highly targeted irradiation associated with minimal 
irradiation to surrounding normal tissue. The results 
demonstrate that appropriate combinations of radiation 
techniques with intra-arterial and systemic chemotherapy 
may significantly improve a patient’s quality of life by 
improving the treatment response and minimizing 
the potential for late radiation effects in surrounding 
structures. 
Neither patient showed signs of recurrence or adverse 
effects during a 16 month follow-up period. In conclusion, 
HT may be beneficial for select patients with advanced 
HCC.
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